Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 46Pituitary Neoplasms 19Neoplasms 14Thyroid Neoplasms 13Pheochromocytoma 13Thyroid Carcinoma, Anaplastic 12Thyroid Cancer, Papillary 12Neoplasm Metastasis 12Adrenocortical Carcinoma 11Paraganglioma 9Insulinoma 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Somatostatinoma 8Glucagonoma 8Colorectal Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Islet Cell 8Pancreatic Neoplasms 7Gastrinoma 7Carcinoma, Neuroendocrine 7Breast Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Adenoma, Islet Cell 6Small Cell Lung Carcinoma 5Multiple Endocrine Neoplasia Type 1 5Lung Neoplasms 5Gastro-enteropancreatic neuroendocrine tumor 5

Interventions

Receptor-Like Protein Tyrosine Phosphatases, Class 2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Malignant Carcinoid Syndrome × Endocrine × Clear all
NCT00092287 2020-04-30

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Ipsen

Phase 3 Terminated
4 enrolled
Endocrine

Malignant Carcinoid Syndrome, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡